Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Xerostomia 1Oligodendroglioma 1Neuroblastoma 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1Adenoviridae Infections 1

Interventions

Temozolomide 107Radiotherapy 60Radiation 28Bevacizumab 19Magnetic Resonance Spectroscopy 16Nivolumab 15Surgical Procedures, Operative 12Irinotecan 11Cyclophosphamide 10Specimen Handling 9Chemotherapy, Adjuvant 9Radiotherapy, Intensity-Modulated 8Radiosurgery 8O(6)-benzylguanine 8Carmustine 8poly ICLC 7pembrolizumab 7motexafin gadolinium 7fludarabine 7Leukapheresis 7Flucytosine 7sargramostim 6Radiotherapy, Conformal 6Erlotinib Hydrochloride 6Lomustine 5Ipilimumab 5Imiquimod 5Imatinib Mesylate 5Hydroxyurea 5Granulocyte-Macrophage Colony-Stimulating Factor 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Glioblastoma × Genetic Engineering × Clear all
NCT01156584 2018-05-21

A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma

Tocagen Inc.

Phase 1 Completed
54 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡